Nick Boucher
YOU?
Author Swipe
View article: Cost-Effectiveness of Treatments for Diabetic Macular Edema: Simulated Bevacizumab-First Step Therapy Versus Real-World Practice
Cost-Effectiveness of Treatments for Diabetic Macular Edema: Simulated Bevacizumab-First Step Therapy Versus Real-World Practice Open
Purpose: To compare the incremental cost-effectiveness of a clinical trial-simulated step-therapy versus real-world treatment for diabetic macular edema (DME). Methods: A theoretical Markov model (follow-up of 2 years and lifetime of 17 ye…
View article: Treatment Patterns and Long-term Outcomes with Anti–VEGF Therapy for Retinal Vein Occlusion
Treatment Patterns and Long-term Outcomes with Anti–VEGF Therapy for Retinal Vein Occlusion Open
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
View article: Maintaining driving vision after intravitreal anti-VEGF therapy in patients with neovascular AMD and diabetic macular edema: a plain language summary of publication
Maintaining driving vision after intravitreal anti-VEGF therapy in patients with neovascular AMD and diabetic macular edema: a plain language summary of publication Open
What is this summary about? This is the summary of an article published in Ophthalmology Retina . This summary presents results from a study that used information from a United States (US) healthcare database to look at how intravitreal in…
View article: Levodopa is associated with reduced development of new-onset geographic atrophy in patients with age-related macular degeneration
Levodopa is associated with reduced development of new-onset geographic atrophy in patients with age-related macular degeneration Open
Background Geographic atrophy (GA) is a significant cause of vision loss in patients with age-related macular degeneration (AMD). Current treatments are limited to anti-complement drugs, which have limited efficacy to delay progression wit…
View article: Bevacizumab First in DRCR Protocol AC vs Real-World Physician Treatment Choice for Diabetic Macular Edema: Two-Year Cost Analysis
Bevacizumab First in DRCR Protocol AC vs Real-World Physician Treatment Choice for Diabetic Macular Edema: Two-Year Cost Analysis Open
Purpose: To compare the modeled costs of the Protocol AC bevacizumab-first treatment protocol (with a switch to aflibercept for sub-responders) with real-world costs for treatment-naïve patients with diabetic macular edema (DME) over a 2-y…
View article: Impact of anti-VEGF treatment on development of proliferative diabetic retinopathy in routine clinical practice
Impact of anti-VEGF treatment on development of proliferative diabetic retinopathy in routine clinical practice Open
Background This study evaluated impact of anti–vascular endothelial growth factor (VEGF) treatment on proliferative diabetic retinopathy (PDR) development among patients with non-proliferative diabetic retinopathy (NPDR) in US real-world c…
View article: Evolving Treatment Patterns in Diabetic Macular Edema Between 2015 and 2020
Evolving Treatment Patterns in Diabetic Macular Edema Between 2015 and 2020 Open
Purpose: To explore the recent evolution of diabetic macular edema (DME) treatment practice patterns over 5 years among retina specialists in the United States. Methods: This retrospective analysis assessed 306 700 eyes with newly diagnose…
View article: Incidence of Retinal Artery and Vein Occlusions During the COVID-19 Pandemic
Incidence of Retinal Artery and Vein Occlusions During the COVID-19 Pandemic Open
BACKGROUND AND OBJECTIVE: To examine whether new cases of retinal artery occlusion (RAO) or retinal vein occlusion (RVO) increased during the coronavirus 209 (COVID-19) pandemic. PATIENTS AND METHODS: This was a retrospective cohort study …
View article: Antivascular Endothelial Growth Factor Dosing Frequency and Visual Outcomes in Macular Edema Following Central Retinal Vein Occlusion
Antivascular Endothelial Growth Factor Dosing Frequency and Visual Outcomes in Macular Edema Following Central Retinal Vein Occlusion Open
Purpose: We evaluated the relationship between dosing frequency of intravitreal antivascular endothelial growth factor (anti-VEGF) agents and visual acuity (VA) outcomes over 2 years in eyes with macular edema (ME) secondary to central ret…
View article: Visual Acuity Outcomes in Patients Receiving Frequent Treatment of Neovascular Age-Related Macular Degeneration in Clinical Practice
Visual Acuity Outcomes in Patients Receiving Frequent Treatment of Neovascular Age-Related Macular Degeneration in Clinical Practice Open
Purpose: This work evaluates dosing frequency with intravitreal antivascular endothelial growth factor (anti-VEGF) agents over 2 years and visual acuity (VA) outcomes in neovascular age-related macular degeneration (nAMD). Methods: This re…
View article: Evaluation of Patients Receiving Intravitreal Antivascular Endothelial Growth Factor for Diabetic Macular Edema in Clinical Practice in the United States
Evaluation of Patients Receiving Intravitreal Antivascular Endothelial Growth Factor for Diabetic Macular Edema in Clinical Practice in the United States Open
Purpose: We assessed the effect of treatment frequency with intravitreal antivascular endothelial growth factor (anti-VEGF) agents on visual acuity (VA) in diabetic macular edema (DME). Methods: This retrospective analysis assessed electro…